Abstract: The co-inhibitory receptor TIGIT consists of an immunoglobulin and an immunoreceptor tyrosine inhibitory motif, which is primarily expressed on the surface of activated T cells and innate immune lymphocytes. TIGIT is up-regulated in skin tumors such as melanoma and cutaneous T-cell lymphoma and is negatively correlated with the disease severity of inflammatory skin diseases such as psoriasis and atopic dermatitis. Based on the current research status at home and abroad, this paper reviews the update of TIGIT and related skin diseases.

Key words: TIGIT, melanoma, cutaneous T-cell lymphoma, lupus erythematosus, psoriasis